Expert oncologist Sandip Patel, MD, discusses treatment decisions for a 62-year-old female with squamous cell lung cancer, highlighting the use of CTLA4 and PD1 inhibitors based on subgroup analysis.
A 62-Year-Old Female with Lung Cancer
Key insight into ongoing challenges and unmet needs in non-small cell lung cancer treatment, including specific patient populations and potential solutions through clinical trials.
Expert perspectives on the significance and limitations of PD-L1 testing in non-small cell lung cancer and the importance of integrating genomic characterization for informed treatment choices.
A concise review of five-year updates from pivotal immunotherapy studies in lung cancer, highlighting the durability of responses and treatment options for high-risk disease
Sandip Patel, MD, discusses the durability of immunotherapy responses, updated survival data from clinical trials, and considerations for patients in the metastatic lung cancer setting.
Insight into key patient characteristics and considerations in determining the optimal approach for treating metastatic non-small cell lung cancer, including the role of chemotherapy, immunotherapy, and targeted therapy.
Expert Sandip Patel, MD, looks toward the promising future of lung cancer research, including targeted therapies, novel immunotherapy approaches, and the importance of biomarkers in guiding treatment decisions.